Drug
Mirvetuximab Soravtansine
Drug Profile
| Therapeutic Class | Antibody-Drug Conjugates (ADCs) |
| Drug Class | — |
| Group | ADC |
| Mechanism of Action | Folate Receptor α targeting ADC |
| Half-life | 4.8 d |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Expected radiosensitizing by maytansinoid anti-tubulin class effect (G2/M arrest), FRα-restricted (Mortaja et al., NPJ Precision Oncology, 2025; Adams et al., Nature Communications, 2016). Antigen restriction theoretically limits normal-tissue sensitization, though the drug's baseline ocular/corneal and neuropathy adverse events are class-specific concerns.
Data on this page refer exclusively to patients treated with
Mirvetuximab Soravtansine combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
ADC group page.